Ascendis Pharma AS
(NAS:ASND)
$
137.5
-2.81 (-2%)
Market Cap: 8.39 Bil
Enterprise Value: 8.62 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 71/100 Ascendis Pharma A/S at Morgan Stanley Healthcare Conference Transcript
Sep 10, 2019 / 06:55PM GMT
Release Date Price:
$105.31
(-0.82%)
Unidentified Analyst
Good afternoon. Thank you very much again for coming to the conference. Before I get going, let me read the requisite disclosures. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures or at the registration desk.
I'd like to welcome to the stage from Ascendis Pharmaceuticals, CEO, Jan Mikkelsen; and CFO, Scott Smith. Ascendis is a development-stage biotechnology company. It's applying its TransCon technology to rare endocrine disorders and as well as oncology.
Questions & Answers
Unidentified Analyst;Jan MÃ;ller Mikkelsen;S;President
Ascendis Pharma A;CEO, Member of Executive Board & Executive
I guess if you could start off and kind of talk at a top level about the technology itself, what is TransCon?
¸ - /
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot